TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05819567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Newly Developed Ankle Brace
Description: The ankle brace is made of gripping tissue and includes two straps and one latex wedge. The purpose of this brace is to lift up the plantar arch.
Study: NCT05150236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Patients will be given 7.5GBq of Lu-PSMA every 6 weeks up to 6 cycles unless there is unacceptable toxicity, commencing following result of 68Ga-PSMA PET within 28 days of registration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will be given 3mg/kg of Ipilimumab every 6 weeks up to 4 doses unless there is unacceptable toxicity, concurrently with Lu-PSMA and Nivolumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will be given 1mg/kg of Nivolumab every 3 weeks up to 8 doses, concurrently with Lu-PSMA and Ipilimumab unless there is unacceptable toxicity. Followed by 480mg nivolumab monotherapy commencing at week 32. Nivolumab monotherapy will be given to patients every 4 weeks up to 18 doses, or until disease progression or unacceptable toxicity.
Study: NCT05132413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
Description: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
Description: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Description: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Study: NCT04968522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride 18 MG
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamphetamine sulfate
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
Study: NCT05790642

Intervention type: DEVICE
Intervention: Pulse wave measurement and analysis
Description: Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.

Intervention type: DEVICE
Intervention: Pulse wave measurement and analysis
Description: Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.

Intervention type: DEVICE
Intervention: Pulse wave measurement and analysis
Description: Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.

Intervention type: DEVICE
Intervention: Pulse wave measurement and analysis
Description: Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.

Intervention type: DEVICE
Intervention: Pulse wave measurement and analysis
Description: Different contact-less and cuff-less pulse wave measurements will be used and compared to cuff-based reference method.
Study: NCT05212779

Intervention type: DIAGNOSTIC_TEST
Intervention: Signatera testing
Description: 26mL blood for the first blood draw and tissue sample. 20mL blood all subsequent draws.

Intervention type: DIAGNOSTIC_TEST
Intervention: Altera Testing
Description: 6ml blood and tissue sample.
Study: NCT04928807

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Short course radiotherapy sequential camrelizumab and chemotherapy
Description: Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy sequential camrelizumab and chemotherapy
Description: Short course radiotherapy, 5 \* 5Gy, once a day, 5Gy each time, for 5 days, continuous irradiation, three-dimensional 3D-CRT or IMRT technology is recommended camrelizumab 200 mg , D1, intravenous drip, q3w, 2 cycles before operation, postoperative adjuvant treatment, the longest medication time of camrelizumab was less than 1 year during the whole study period; Capecitabine 1000 mg / m2, twice a day, oral, 1-14 days, then rest for 7 days, q3w, 2 cycles before operation and 6 cycles after operation; Oxaliplatin 130 mg / m2, D1, intravenous infusion 2 hours, q3w, 2 cycles before operation, 6 cycles after operation
Study: NCT05205109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-037
Description: Part I : ATG-037 will be administered orally once a day (QD) on D-2, then multiple doses of ATG-037 will be administered orally BID for every day from C1D1. A treatment cycle will be defined as 21 days.~Part II: ATG-037 will be administered orally BID for every day from C1D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA ®( Pembrolizumab)
Description: Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1.
Study: NCT06545409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with 0.25% bupivacaine
Description: While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.25% bupivacaine is administered superficially to the intercostal muscle.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided Serratus Posterior Superior Intercostal Plane Block performed with a placebo solution (0.9% NaCl)
Description: While the patient is in the prone or the sitting position, a high-frequency linear transducer is placed transversely at the level of the scapular spine, visualizing the upper medial border of the scapula, trapezius muscle, rhomboid major, serratus posterior superior muscle, and the second and third ribs. Next, the transducer is rotated to obtain an oblique view, including the upper medial border of the scapula. The needle is then advanced immediately medial to the scapula, aiming for the area between the second and third ribs to reach the fascial plane between the serratus posterior superior muscle and intercostal muscles using the in-plane technique. Once the needle contacts the rib, 30 mL of 0.9% NaCl is administered superficially to the intercostal muscle
Study: NCT05364580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROTOXIN
Description: Botulinum toxin Type A

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Botulinum toxin Type A
Study: NCT04419805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Palatal TAD
Description: A single mini-screw inserted in the mid-palate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two buccal TADs
Description: Two buccal TADs inserted in the upper jaw
Study: NCT05815537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Reverberation
Description: The exposure to low-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., small classroom.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Reverberation
Description: The exposure to high-reverberation is by presenting auditory stimuli to participants that are digitally processed to contain auditory cues that sound more or less reverberant, e.g., large lecture hall/auditorium.
Study: NCT06484374

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Robot-assisted minimally invasive treatment
Description: An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive treatment
Description: An automatic surgical path planning system using artificial intelligence fused with neuroimaging is used to determine the surgical incision and drilling points; the principles followed include but are not limited to: avoidance of important functional areas such as language and motor cortex; avoidance of vascular densely populated areas; and individualized optimal paths for the three-dimensional morphology of the hematoma and spatial orientation.
Study: NCT05125081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pill (marketed product in China)
Description: LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liuwei Dihuang Pill（placebo ）
Description: LDP group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo group and LDP group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the LDP group and placebo group at a ratio of 1:1. The drug was administered for 48 weeks, 3 times a day, 8 pills each time.
Study: NCT05221138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116
Description: VV116 oral tablets, 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116
Description: VV116 oral tablets, 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116
Description: VV116 oral tablets, 400mg
Study: NCT06276400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotion valence
Description: Positive vs. Negative (temporally extended sequence)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time
Description: ∆ Temporal evidence (i.e. relative time difference of stimulus-type exposure across a sequence: 1200 vs. 1800)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS Stimulation
Description: FPl vs. mid-LPFC vs. non-PFC Control (S1); Specific LPFC region (vs. non-PFC active Control) function is manipulated with an inhibitory TMS protocol (cTBS).
Study: NCT06402942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified occupational therapy programme
Description: Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Classic occupational therapy programme
Description: Gamified occupational therapy program for the experimental group and classical occupational therapy program for the control group, which will be applied to both groups for eight weeks
Study: NCT06056089

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ready-to-use supplementary food (RUSF)
Description: standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/media/16636/file/S0000248-RUSF-Specification.pdf

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (RUTF)
Description: standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (RUTF)
Description: standard formulation meeting UNICEF specifications: https://www.unicef.org/supply/sites/unicef.org.supply/files/2023-04/U239977-RUTF-Novel-Specification.pdf
Study: NCT06146192

Intervention type: DRUG
Intervention: Colchicine
Description: colchicine 1-2 mg/day
Study: NCT06096584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple Injection Perisartorius block
Description: Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone.~Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual sub sartorial block
Description: Drug: Bupivacaine 0.25 % mixed with 2 mg dexamethasone~Patients will receive a combination of femoral triangle block and distal ACB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral triangle block
Description: Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral triangle block
Description: Femoral triangle block will be given just (1-2 cm) proximal to the apex of the femoral tringle which is the point at which the medial border of the sartorius muscle (STM) meets the medial border of the adductor longus muscle (ALM). Ten ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected just below the STM.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal adductor canal block
Description: Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal adductor canal block
Description: Another 20 ml of 0.25 % bupivacaine mixed with 2 mg dexamethasone will be injected in the lower one-third of the adductor canal.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprasartorial plane block
Description: Patients will receive a third injection of 10 ml of 0.25 % bupivacaine superficial to the sartorius under the facia lata
Study: NCT06087575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supira System
Description: The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
Study: NCT05864118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory pathogen panel PCR test
Description: Respiratory pathogen panel PCR test and COVID-19 antibody test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory pathogen panel PCR test
Description: Respiratory pathogen panel PCR test and COVID-19 antibody test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory pathogen panel PCR test
Description: Respiratory pathogen panel PCR test and COVID-19 antibody test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 antibody test
Description: COVID-19 antibody test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 antibody test
Description: COVID-19 antibody test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 antibody test
Description: COVID-19 antibody test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COVID-19 antibody test
Description: COVID-19 antibody test
Study: NCT04524767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: Screening Brief Intervention and Referral to Treatment (SBIRT) is an evidence-based approach designed to provide screening, brief intervention, and referral to more intensive treatment for people at risk of developing mental disorders, including depression. SBIRT is composed of three core components: screening with a validated instrument, brief intervention, referral to treatment. Motivational Interviewing (MI) is the brief intervention most commonly used in SBIRT. MI is an empirically tested, person-centered, behavior change intervention designed to guide, elicit, and strengthen motivation for change. Subjects enrolled in the experimental SBIRT arm will receive up to a maximum of six sessions of MI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral as Usual
Description: We will utilize depression educational brochures describing the nine hallmark symptoms of depression symptoms and the importance of seeking treatment from pamphlets from the National Institute of Mental Health (NIMH). Subjects will also receive a list of referral sites in the study's catchment area of Upper Manhattan
Study: NCT04437498

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: non invasive vagal nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nVNS
Description: active vns stimulation
Study: NCT05693909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Capsules for oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Capsules for oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: Capsules for oral intake
Study: NCT06401278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: It will be performed by using the TENS device on acupoint (TEAS) as the following:~The patients will be placed in a relaxed comfortable sitting position with their back well supported. for 40 min three times weekly for a total of 6 weeks.The adhesive electrodes of the TENS device will be placed on the selected acupoint bilaterally Nei-Guan (PC6), Taichong (LR3), and Sanyinjiao (SP6)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (group b):
Description: TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 min three times weekly for a total of 6 weeks.
Study: NCT04689074

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, PBMC and blood for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening

Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Study: NCT05525247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-3010
Description: Intravenous (IV) infusion over 30 minutes on day 1 of each 21-day cycle